OTC GERD aids
This article was originally published in The Tan Sheet
Executive Summary
OTC medications "have a clinically meaningful role in treating" gastroesophageal reflux disease and provide "rapid, effective and safe relief" of episodic heartburn for periods not exceeding four weeks, an 1American Gastroenterological Association consensus panel report says. In treatment guidelines released Nov. 14, AGA panel concludes 60%-70% of patients studied in randomized clinical trials responded to acid neutralization or acid inhibition by OTC medications, such as antacids, H2 antagonists and H2/antacid combinations. Citing data from J&J/Merck's FACT study of 1,640 patients who were randomly assigned the H2/antacid combination Pepcid Complete, famotidine alone, antacid alone or placebo, AGA panel asserts H2/antacid combination "provides an incremental improvement in efficacy, compared with the individual agents." J&J/Merck provided an unrestricted educational grant for the AGA panel's work...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.